Test Price
2,800 AED✅ Home Collection Available
SCNN1G Gene Liddle Syndrome Genetic Test (NGS) in UAE | 2,800 AED
Executive Summary & Core Metrics
- Accuracy Guarantee: 99.9% diagnostic sensitivity via ISO-certified Next-Generation Sequencing (NGS) with full exon and intronic coverage of the SCNN1G gene.
- Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection available daily from 8 AM to 11 PM across Dubai and select UAE emirates.
- Clinical Guidance: Complimentary telephonic post-test consultation with a DHA-licensed Consultant Medical Geneticist to contextualize results and recommend next steps.
- Insurance & Billing: Direct billing verification and insurance pre-approval via WhatsApp: +971 54 548 8731.
ISO 9001:2015 (Cert: INT/EGQ/2509DA/3139) | DHA Licensed Facility: 1143 | Corporate Lab: DNA Labs UAE
Test Overview & Methodology
This Next-Generation Sequencing (NGS) assay analyzes the SCNN1G gene to diagnose Liddle syndrome—a rare autosomal dominant form of hypertension caused by constitutive activation of the epithelial sodium channel (ENaC) in the distal nephron. Pathogenic gain-of-function variants result in unchecked sodium reabsorption, volume expansion, and low-renin, low-aldosterone hypertension. Early molecular confirmation enables targeted pharmacotherapy with ENaC blockers such as amiloride or triamterene, mitigating the risk of stroke, left ventricular hypertrophy, and chronic kidney disease progression.
| Feature | Our Test (NGS) | Conventional Sanger Sequencing |
|---|---|---|
| Precision | Full gene coverage including deep intronic regions, splice-site variants, and large structural rearrangements | Limited to coding exons; may miss intronic mutations and large deletions |
| Methodology | Next-Generation Sequencing (NGS) with paired-end 150 bp reads at >100× depth | Targeted Sanger sequencing per amplicon |
| Turnaround | 3–4 weeks | 4–6 weeks (multiple amplicons required) |
Physician Insight & Safety Protocols
“Liddle syndrome is a clinically actionable monogenic hypertension that mimics primary hyperaldosteronism. A definitive molecular diagnosis allows the clinician to transition patients from broad-spectrum antihypertensives to low-dose amiloride, drastically improving blood pressure control with fewer metabolic side effects. I always emphasize that genetic test results must be interpreted alongside plasma renin activity, serum aldosterone, and potassium levels. This test is a diagnostic adjunct, not a standalone screening tool—comprehensive nephrology and genetic counseling are mandatory for all patients and families.”
— Lina Osama Zaki Quteineh, Consultant Medical Genetics | DHA Registration ID: 9294403
⚠️ Important Medication Advisory
Do not alter, pause, or cease any prescribed antihypertensive medication—including amiloride, triamterene, spironolactone, or other diuretics—without explicit direction from your treating physician. Sudden withdrawal of ENaC blocker therapy may provoke rebound hypertension and acute cardiovascular events.
Exclusion Criteria & Emergency Referral
- This molecular test is not indicated for acute hypertensive crises or emergency room triage; results require 3–4 weeks.
- Patients with active hemolysis, recent blood transfusion (within 14 days), or major surgical procedures should defer sample collection until clinically stable.
- If you experience sudden severe headache, blurred vision, exertional chest pain, dyspnea, or focal neurological deficits, call 998 or proceed to the nearest emergency department immediately.
- Pre-test genetic counseling is mandatory. Direct-to-consumer ordering without a clinical consultation and pedigree analysis is not supported by our laboratory.
Patient FAQ & Clinical Guidance
1. What does the SCNN1G gene Liddle syndrome test detect?
The assay identifies pathogenic single-nucleotide variants, small insertions and deletions, and copy-number variants in the SCNN1G gene that cause Liddle syndrome. This hereditary condition leads to overactive epithelial sodium channels in the kidney, resulting in early-onset, salt-sensitive hypertension with suppressed renin and aldosterone levels. Detection of a confirmed pathogenic variant allows for tailored management with amiloride therapy and family cascade screening.
2. How is the sample collected and what preparation is required?
A licensed phlebotomist will collect a whole blood sample (2–5 mL in EDTA) at your residence or office via our VIP Mobile Phlebotomy service between 8 AM and 11 PM. Alternatively, an extracted DNA sample or a dried blood spot on an FTA card may be submitted. No fasting is required, but you must provide a copy of your signed genetic counseling consent form and a three-generation pedigree chart at the time of collection.
3. When will results be ready and what is the follow-up process?
Final results are delivered within 3–4 weeks from sample receipt. A DHA-licensed Consultant Medical Geneticist will contact you by telephone to explain the findings, discuss implications for blood pressure management and family member testing, and schedule a referral to a nephrologist or genetic counselor if indicated.
UAE Regulatory & Data Privacy Adherence
This genetic testing service operates in full compliance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) for secure handling and storage of patient genomic data, and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields for digital health information governance. Clinical safety and patient consent protocols adhere to Federal Decree-Law No. 4 of 2016 on Medical Liability. All samples are processed at DNA Labs UAE—a DHA-licensed facility (License No. 1143) with ISO 9001:2015 certification—ensuring traceability, confidentiality, and clinical validity.
Clinical & Logistical Metadata
| Test Name | SCNN1G Gene Liddle Syndrome Genetic Test (NGS) |
| Price (AED) | 2,800 |
| Turnaround Time | 3–4 weeks |
| Sample Type / Matrix | Whole blood (EDTA), extracted genomic DNA, or dried blood spot on FTA card |
| Methodology Used | Next-Generation Sequencing (NGS) – full gene sequencing including intronic regions |
| ICD-10-CM Code | I10, Z13.71 |
| LOINC Code | 98118-1 |
| DHA Facility License & Laboratory Address | DHA License No. 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians